Thymia
London, EnglandFounded 2020
- Seed
Thymia develops voice biomarker technology that analyzes speech in real time to identify health and wellbeing signals, including indicators related to mental health, diabetes, fatigue, and stress. Its platform is designed to integrate with healthcare and voice systems, turning signals from as little as 15 seconds of speech into recommendations and actions.
- RaisedTotal raised
- $5.6M
- Jul 2023Latest priced round, Jul 2023
- Seed
- Investors
- 11
- Founded
- 2020
- Employees
- 11–50
reccy insights
On Sep 29, 2026, a published item associated with Thymia discussed the potential for short voice recordings to support type 2 diabetes screening. This aligns with the company's expansion from a mental-health assessment focus toward voice-based signals across multiple health and wellbeing areas. Thymia's platform materials describe Apollo for clinical detection, including depression, anxiety and active type 2 diabetes, and Helios for monitoring signals such as fatigue, stress and cognitive load. Earlier milestones include the July 2023 seed financing of $3,070,400, with Kodori AG and Calm/Storm VC identified as leads, followed by a $1,414,607 equity crowdfunding round on Jul 28, 2023. In August 2024, the company was recognized as a small-company leader in gender-diversity sourcing. These milestones point to continued development of its voice-analysis offering, but the available profile does not establish a newer financing, named partnership, or leadership change.
Written by reccy's AI from company sites, press and funding records · updated Oct 2026
What makes Thymia distinct
- 01Analyzes speech in real time, with detection designed to work from as little as 15 seconds of speech.
- 02Combines voice-biomarker signals with industry-specific policy reasoning to produce actionable recommendations.
- 03Offers Apollo for clinical health detection and Helios for wellbeing and safety monitoring across live voice interactions.
- 04Apollo is registered with the MHRA as a Class I medical device under UK MDR 2002 and is described for pre-screening, triage and remote monitoring.
- 05Supports cloud and on-premises deployment.
Technology & products
- thymia Platform
An AI-driven platform that assesses voice, movement and behavioral data to identify mental-health conditions and symptoms through a Wellness Check.
- Neural morphemes®: foundational speech units used to identify patterns that can be combined into voice biomarkers.
- Apollo: voice-based detection of depression, anxiety and active type 2 diabetes.
- Helios: real-time monitoring of fatigue, stress, distress, burnout, emotions and cognitive load.
- Argus: a real-time action system combining biomarker signals with text, conversational context and industry-specific policy logic.
- Architecture-agnostic deployment for cloud or on-premises environments.
Recent updates4
- Oct 14, 2026Partnership
thymia’s voice analysis technology featured in Mazda's empathetic AI exhibit
thymia.ai - Aug 14, 2026Product launch
Understanding the human behind the voice, now a registered medical device
thymia.ai - Apr 21, 2026Partnership
Agora and thymia Partner to Enable Real-Time Health and Safety Intelligence Across Voice Communications
thymia.ai
In the Cortex
- Thymia’s Voice Analysis Technology Featured in Mazda’s Empathetic AI ExhibitThymia · Oct 14, 2026
Funding
- Equity CrowdfundingJul 2023$1.4MLed by Crowdcube
- SeedJul 2023$3.1MLed by Kodori AG, Calm/Storm VC
- Pre-SeedJun 2021$1.1MLed by Calm/Storm VC, Kodori AG
About Thymia
- Products
- thymia Platform
- Leadership
- Emilia Molimpakis, CEO & Co-FounderStefano Goria, CTO & Co-Founder
- Focus areas
- NeuroTechnology, digital health, AI/ML, diagnostics, medical devices, voice biomarkers, health monitoring, wellbeing
- Headquarters
- London, England
- Founded
- 2020
- Employees
- 11–50
- Patents granted
- 1
- Trademarks
- 1